FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048458238> ?p ?o ?g. }

• W3048458238 endingPage "1019" @default.
• W3048458238 startingPage "1006" @default.
• W3048458238 abstract "Patients with diabetes who had a recent myocardial infarction (MI) are at high risk of cardiovascular events. Therefore, risk assessment is important for treatment and shared decisions. We used data from EXAMINE trial to investigate whether a multi-proteomic approach would provide specific proteomic signatures and also improve the prognostic capacity for determining the risk of cardiovascular death, MI, stroke, heart failure [HF], all-cause death, and combinations of these outcomes. 93 circulating proteins (92 from the Olink® CVDII plus troponin) were assessed in 5131 patients. Cox, competing risks, and reclassification measures were applied. The clinical model showed good discrimination and calibration for all outcomes. On top of the clinical model that included age, sex, smoking, diabetes duration, history of MI (prior to the index MI of inclusion), history of HF hospitalization, history of stroke, atrial fibrillation, hypertension, systolic blood pressure, statin therapy, estimated glomerular filtration rate, and study treatment (alogliptin or placebo), troponin and BNP added prognostic information to the composite of cardiovascular death, MI, or stroke (∆C-index + 5%) and cardiovascular death alone (∆C-index + 7%). Troponin, BNP, and TRAILR2 added prognostic information on all-cause death and the composite of cardiovascular death or HF hospitalization. HF hospitalization alone was improved by adding BNP and Gal-9. For MI, troponin, FGF23, and AMBP added prognostic value; whereas for stroke, only troponin added prognostic value (multi-proteomics improved C-index > 3% [p < 0.001] for all the studied outcomes). The addition of the final biomarker selection to the clinical model improved event reclassification (cNRI from + 23% to + 64%). Specifically, the addition of the biomarkers allowed a better classification of patients at low risk (as having “true” low risk) and patients and high risk (as having “true” high risk). These results were consistent for all the studied outcomes with even more marked differences in the fatal events. The addition of multi-proteomic biomarkers to a clinical model in this population with diabetes and a recent MI allowed a better risk prediction and event reclassification, potentially helping for better risk assessment and targeted treatment decisions. T2D type 2 diabetes, MI myocardial infarction, CV cardiovascular, HFH heart failure hospitalization, Δ delta, cNRI continuous net reclassification index, BNP brain natriuretic peptide, TRAILR2 trail receptor 2 (or death receptor 5), Gal-9 galectin-9, FGF23 fibroblast growth factor 23." @default.
• W3048458238 created "2020-08-18" @default.
• W3048458238 creator A5001704230 @default.
• W3048458238 creator A5012514694 @default.
• W3048458238 creator A5020254504 @default.
• W3048458238 creator A5021920910 @default.
• W3048458238 creator A5028145932 @default.
• W3048458238 creator A5036821495 @default.
• W3048458238 creator A5056816871 @default.
• W3048458238 date "2020-08-13" @default.
• W3048458238 modified "2023-10-07" @default.
• W3048458238 title "Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial" @default.
• W3048458238 cites W1813115710 @default.
• W3048458238 cites W1911269322 @default.
• W3048458238 cites W197402492 @default.
• W3048458238 cites W2001984572 @default.
• W3048458238 cites W2020413892 @default.
• W3048458238 cites W2038981426 @default.
• W3048458238 cites W2071090755 @default.
• W3048458238 cites W2073054137 @default.
• W3048458238 cites W2076335162 @default.
• W3048458238 cites W2103645914 @default.
• W3048458238 cites W2113538868 @default.
• W3048458238 cites W2127854619 @default.
• W3048458238 cites W2144325462 @default.
• W3048458238 cites W2149516335 @default.
• W3048458238 cites W2150959326 @default.
• W3048458238 cites W2164168324 @default.
• W3048458238 cites W2168261002 @default.
• W3048458238 cites W2169618461 @default.
• W3048458238 cites W2170271198 @default.
• W3048458238 cites W2198866495 @default.
• W3048458238 cites W2273304042 @default.
• W3048458238 cites W2314817524 @default.
• W3048458238 cites W2331274940 @default.
• W3048458238 cites W2413776824 @default.
• W3048458238 cites W2508503189 @default.
• W3048458238 cites W2555022685 @default.
• W3048458238 cites W2580226796 @default.
• W3048458238 cites W2592175035 @default.
• W3048458238 cites W2594341951 @default.
• W3048458238 cites W2596179513 @default.
• W3048458238 cites W2618557766 @default.
• W3048458238 cites W2742106012 @default.
• W3048458238 cites W2766857707 @default.
• W3048458238 cites W2772204795 @default.
• W3048458238 cites W2790460733 @default.
• W3048458238 cites W2886392580 @default.
• W3048458238 cites W2894746763 @default.
• W3048458238 cites W2896894922 @default.
• W3048458238 cites W2946963067 @default.
• W3048458238 cites W2948897229 @default.
• W3048458238 cites W2955202456 @default.
• W3048458238 cites W2996957335 @default.
• W3048458238 cites W3175417087 @default.
• W3048458238 doi "https://doi.org/10.1007/s00392-020-01729-3" @default.
• W3048458238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32789678" @default.
• W3048458238 hasPublicationYear "2020" @default.
• W3048458238 type Work @default.
• W3048458238 sameAs 3048458238 @default.
• W3048458238 citedByCount "20" @default.
• W3048458238 countsByYear W30484582382020 @default.
• W3048458238 countsByYear W30484582382021 @default.
• W3048458238 countsByYear W30484582382022 @default.
• W3048458238 countsByYear W30484582382023 @default.
• W3048458238 crossrefType "journal-article" @default.
• W3048458238 hasAuthorship W3048458238A5001704230 @default.
• W3048458238 hasAuthorship W3048458238A5012514694 @default.
• W3048458238 hasAuthorship W3048458238A5020254504 @default.
• W3048458238 hasAuthorship W3048458238A5021920910 @default.
• W3048458238 hasAuthorship W3048458238A5028145932 @default.
• W3048458238 hasAuthorship W3048458238A5036821495 @default.
• W3048458238 hasAuthorship W3048458238A5056816871 @default.
• W3048458238 hasBestOaLocation W30484582382 @default.
• W3048458238 hasConcept C115725540 @default.
• W3048458238 hasConcept C126322002 @default.
• W3048458238 hasConcept C127413603 @default.
• W3048458238 hasConcept C134018914 @default.
• W3048458238 hasConcept C164705383 @default.
• W3048458238 hasConcept C2778198053 @default.
• W3048458238 hasConcept C2780645631 @default.
• W3048458238 hasConcept C36036425 @default.
• W3048458238 hasConcept C500558357 @default.
• W3048458238 hasConcept C50382708 @default.
• W3048458238 hasConcept C555293320 @default.
• W3048458238 hasConcept C71924100 @default.
• W3048458238 hasConcept C78519656 @default.
• W3048458238 hasConceptScore W3048458238C115725540 @default.
• W3048458238 hasConceptScore W3048458238C126322002 @default.
• W3048458238 hasConceptScore W3048458238C127413603 @default.
• W3048458238 hasConceptScore W3048458238C134018914 @default.
• W3048458238 hasConceptScore W3048458238C164705383 @default.
• W3048458238 hasConceptScore W3048458238C2778198053 @default.
• W3048458238 hasConceptScore W3048458238C2780645631 @default.
• W3048458238 hasConceptScore W3048458238C36036425 @default.
• W3048458238 hasConceptScore W3048458238C500558357 @default.
• W3048458238 hasConceptScore W3048458238C50382708 @default.
• W3048458238 hasConceptScore W3048458238C555293320 @default.

• next